Ventricular tachycardia (VT) is an abnormal heart rhythm originating from the lower chambers of the heart (ventricles). In the general population, the incidence of VT is estimated to be around 0.1 to 0.4 per 1,000 people per year. However, among patients with heart disease or those who have undergone certain cardiac procedures, the prevalence can be much higher. For example, in patients with heart failure or previous myocardial infarction, the prevalence of VT can range from 5% to 15%.
VT is also more commonly observed in older individuals due to the increased likelihood of developing structural heart disease as age advances or in certain patient populations such as those with genetic channelopathies, electrolyte imbalances, or certain medications that can predispose individuals to arrhythmias. Additionally, VT can manifest as both sustained and non-sustained episodes, with the latter being more common.
These rhythms can be life-threatening and difficult to control. Patients typically have implantable defibrillators; however, patients can receive multiple shocks despite aggressive medications. Catheter ablation is considered the most effective non-pharmacological approach to reducing the recurrence of VT; however, this procedure requires specialized techniques and a team of electrophysiologists and surgeons to be successful.